Format

Send to:

Choose Destination
See comment in PubMed Commons below
BMJ. 2009 May 29;338:b1846. doi: 10.1136/bmj.b1846.

Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial.

Author information

  • 1Norwegian Colorectal Cancer Prevention (NORCCAP) Centre, Cancer Registry of Norway, Montebello, NO-0310 Oslo, Norway. hofg@online.no

Abstract

OBJECTIVE:

To determine the risk of colorectal cancer after screening with flexible sigmoidoscopy.

DESIGN:

Randomised controlled trial.

SETTING:

Population based screening in two areas in Norway-city of Oslo and Telemark county (urban and mixed urban and rural populations).

PARTICIPANTS:

55 736 men and women aged 55-64 years.

INTERVENTION:

Once only flexible sigmoidoscopy screening with or without a single round of faecal occult blood testing (n=13 823) compared with no screening (n=41 913).

MAIN OUTCOME MEASURES:

Planned end points were cumulative incidence and mortality of colorectal cancer after 5, 10, and 15 years. This first report from the study presents cumulative incidence after 7 years of follow-up and hazard ratio for mortality after 6 years.

RESULTS:

No difference was found in the 7 year cumulative incidence of colorectal cancer between the screening and control groups (134.5 v 131.9 cases per 100 000 person years). In intention to screen analysis, a trend towards reduced colorectal cancer mortality was found (hazard ratio 0.73, 95% confidence interval 0.47 to 1.13, P=0.16). For attenders compared with controls, a statistically significant reduction in mortality was apparent for both total colorectal cancer (hazard ratio 0.41, 0.21 to 0.82, P=0.011) and rectosigmoidal cancer (0.24, 0.08 to 0.76, P=0.016).

CONCLUSIONS:

A reduction in incidence of colorectal cancer with flexible sigmoidoscopy screening could not be shown after 7 years' follow-up. Mortality from colorectal cancer was not significantly reduced in the screening group but seemed to be lower for attenders, with a reduction of 59% for any location of colorectal cancer and 76% for rectosigmoidal cancer in per protocol analysis, an analysis prone to selection bias.

TRIAL REGISTRATION:

Clinical trials NCT00119912.

PMID:
19483252
[PubMed - indexed for MEDLINE]
PMCID:
PMC2688666
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk